Candriam S.C.A. Repligen Corp Transaction History

Candriam S.C.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$170.78 - $208.42 $230,553 - $281,367	1,350 New	1,350 $248,000
Q1 2023 May 12, 2023	BUY	$154.26 - $198.1 $325,951 - $418,585	2,113 Added 59.44%	5,668 $954,000
Q4 2022 Feb 13, 2023	BUY	$162.42 - $220.56 $577,403 - $784,090	3,555 New	3,555 $601,000
Q4 2021 Feb 10, 2022	SELL	$247.59 - $304.47 $3.48 Million - $4.28 Million	-14,064 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$194.77 - $324.21 $3.2 Million - $5.32 Million	-16,406 Reduced 53.84%	14,064 $4.06 Million
Q2 2021 Jul 20, 2021	BUY	$165.87 - $220.95 $5.05 Million - $6.73 Million	30,470 New	30,470 $6.08 Million

476

55.6M

311K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.09B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.